01 Biofilm-disrupting Enzyme Dressings for Drug-resistant Chronic Ulcers Advanced chronic wound dressings incorporating proteolytic and DNase-based biofilm-disrupting enzymes are gaining adoption for management of multidrug-resistant diabetic foot and venous leg ulcers. These smart matrices selectively degrade extracellular polymeric biofilm structures that inhibit antibiotic penetration and tissue oxygenation. Various specialized diabetic wound centers across Germany and the Netherlands expanded utilization of enzymatic antimicrobial dressings within outpatient limb-preservation programs to reduce chronic ulcer recurrence and lower amputation-related hospitalization burden among aging diabetic populations.
02 Oxygen-generating Microcapsule Therapies for Hypoxic Wound Healing Oxygen-generating chronic wound dressings utilizing calcium peroxide and magnesium peroxide microcapsules are emerging as advanced therapies for ischemic diabetic ulcers with severe tissue hypoxia. These biomaterials enable continuous localized oxygen release directly within wound beds, improving angiogenesis and fibroblast activity without external oxygen systems. In September 2025, researchers presented calcium peroxide xerogel dressing data demonstrating sustained oxygen diffusion and accelerated tissue regeneration in diabetic wound environments. Growing focus on hypoxia-targeted wound healing is accelerating commercialization of oxygen-releasing regenerative dressings globally.
03 Chronic Wound Care Market Investment And Funding Analysis The chronic wound care market is witnessing increasing investment and funding activity driven by rising demand for advanced wound dressings, biologic skin substitutes, antimicrobial therapies, and remote wound monitoring technologies. Investments are primarily focused on commercialization of AI-enabled wound assessment platforms, expansion of regenerative wound healing products, and development of next-generation tissue repair solutions for diabetic foot ulcers, venous leg ulcers, and pressure injuries globally. Following are some major funding and investment activities undertaken by companies in 2025:
04 Key Investment and Funding Activities in Chronic Wound Care Market, 2025 Company Recent Activity Timeline Focus Value Kerecis Manufacturing Expansion Investment February 2025 Kerecis expanded investment in fish-skin-based regenerative wound healing production facilities to increase supply capacity for chronic wound and diabetic ulcer treatment products across North America and Europe. USD 15 Million Mölnlycke Health Care AB Strategic Investment September 2025 Mölnlycke invested in advanced digital wound monitoring and antimicrobial dressing development programs to strengthen chronic wound management capabilities and home healthcare integration. USD 12 Million
01 Increasing Utilization of Remote Wound Monitoring and Growing Adoption of Silver Dressings for Diabetic Foot Ulcers Drives Market The growing integration of remote wound monitoring platforms within home healthcare services is substantially driving demand for digital wound care solutions and advanced dressings for chronic ulcer management. Healthcare providers are increasingly utilizing AI-enabled imaging systems and telehealth-supported wound assessment to reduce hospital readmissions and improve long-term healing outcomes among elderly and immobile patients. In the UK, the National Health Service expanded virtual wound care pathways across community nursing networks during 2025, strengthening adoption of connected chronic wound management technologies nationwide.Increasing prevalence of infected diabetic foot ulcers is significantly accelerating demand for silver-based antimicrobial wound dressings capable of reducing bioburden and managing exudate in chronic wounds. These dressings provide sustained broad-spectrum antimicrobial activity against antibiotic-resistant pathogens while maintaining optimal moisture balance for tissue repair. Major companies including Smith & Nephew plc with ACTICOAT, ConvaTec Group plc with AQUACEL Ag+, and Mölnlycke Health Care AB with Mepilex Ag are expanding advanced silver dressing utilization across diabetic limb-preservation and outpatient wound management programs.
01 Shortage of Certified Wound Care Specialists and High Per-patient Treatment Cost for Advanced Chronic Wound Therapies Restrain Market A significant restraint in the chronic wound care market is the global shortage of certified wound care specialists capable of managing complex diabetic foot ulcers, pressure injuries, and vascular wounds. Advanced therapies such as negative pressure wound systems, bioengineered skin substitutes, and antimicrobial biologics require specialized clinical assessment and monitoring for effective outcomes. Limited availability of trained wound nurses, podiatrists, and tissue viability experts across community and long-term care settings delays appropriate intervention and restricts utilization of advanced chronic wound care technologies.High per-patient treatment costs significantly restrain adoption of advanced chronic wound care products, particularly among elderly and diabetic populations requiring long-duration therapy. Technologies such as bioengineered skin substitutes, negative pressure wound therapy systems, and antimicrobial biologics involve repeated applications, specialist monitoring, and extended outpatient management, increasing overall healthcare expenditure. For example, the US Agency for Healthcare Research and Quality reported diabetic foot ulcer treatment costs can exceed USD 50,000 per patient in severe cases involving infection management and lower-extremity complications, limiting affordability across healthcare systems.
01 Expansion of Hospital-at-home Wound Management Programs and Rising Incidence of Diabetic Foot Complications Offer Growth Opportunities for Market Players The rapid expansion of hospital-at-home and community-based wound management programs is creating strong growth opportunities for advanced chronic wound care technologies. Healthcare providers are increasingly shifting diabetic ulcer, pressure injury, and venous leg ulcer treatment toward home healthcare settings to reduce hospitalization burden and long-term inpatient costs. This transition is accelerating demand for portable negative pressure wound therapy systems, antimicrobial dressings, and remote wound monitoring platforms. Growing integration of telehealth-supported wound assessment is further strengthening commercialization opportunities for connected chronic wound management solutions.The increasing global burden of diabetic foot complications is generating significant growth opportunities for advanced chronic wound care products focused on infection control and limb preservation. Governments and healthcare systems are expanding multidisciplinary diabetic foot prevention programs to reduce lower-extremity amputations and hospitalization costs associated with non-healing ulcers. According to the International Diabetes Federation, diabetes affected approximately 537 million adults globally, substantially increasing chronic ulcer prevalence. Growing focus on early intervention and amputation prevention is accelerating demand for regenerative wound biologics, antimicrobial dressings, and skin substitute technologies.
01 Inconsistent Exudate Management and Supply Chain Disruptions for Advanced Wound Care Materials Challenges Chronic Wound Care Market Growth Variability in exudate absorption capacity and dressing adhesion performance acts as a significant challenge in the chronic wound care market, particularly for highly exudative venous leg ulcers and irregular wound anatomies. Certain foam and hydrofiber dressings experience leakage, edge lifting, or premature saturation under prolonged wear conditions, affecting moisture balance and infection control. Poor dressing conformity around difficult wound sites increases frequency of replacement and nursing intervention, reducing patient compliance and limiting confidence in advanced wound management products across long-duration chronic ulcer treatment settings.Supply chain instability for advanced wound care materials remains a major challenge in the chronic wound care market, particularly for biologic dressings, collagen matrices, silver-based products, and negative pressure wound therapy consumables. Many specialized wound care components rely on temperature-controlled logistics, limited raw material suppliers, and centralized manufacturing facilities. Disruptions in transportation, sterilization capacity, or sourcing of biologic materials can delay product availability and increase procurement costs for hospitals and wound clinics. These vulnerabilities negatively affect treatment continuity and inventory management across chronic wound care networks.